{"name":"Apellis Pharmaceuticals, Inc.","slug":"apellis-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"APL-2","genericName":"APL-2","slug":"apl-2","indication":"Geographic atrophy (age-related macular degeneration)","status":"phase_3"},{"name":"APL-2, Pegcetacoplan","genericName":"APL-2, Pegcetacoplan","slug":"apl-2-pegcetacoplan","indication":"Geographic atrophy (age-related macular degeneration)","status":"phase_3"},{"name":"APL2","genericName":"APL2","slug":"apl2","indication":"Paroxysmal nocturnal hemoglobinuria (PNH)","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Soliris","genericName":"Soliris","slug":"soliris","indication":"Atypical hemolytic uremic syndrome","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"APL-9","genericName":"APL-9","slug":"apl-9","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"APL-2","genericName":"APL-2","slug":"apl-2","phase":"phase_3","mechanism":"APL-2 is a complement C3 inhibitor that blocks the central component of the complement cascade to reduce inflammation and tissue damage.","indications":["Geographic atrophy (age-related macular degeneration)","C3 glomerulopathy","Post-transplant thrombotic microangiopathy"],"catalyst":""},{"name":"Soliris","genericName":"Soliris","slug":"soliris","phase":"marketed","mechanism":"Complement C5","indications":["Atypical hemolytic uremic syndrome","Congenital hemolytic uremic syndrome","Neuromyelitis optica","Paroxysmal nocturnal hemoglobinuria","Refractory generalized myasthenia gravis"],"catalyst":""},{"name":"APL-2, Pegcetacoplan","genericName":"APL-2, Pegcetacoplan","slug":"apl-2-pegcetacoplan","phase":"phase_3","mechanism":"Pegcetacoplan is a complement C3 inhibitor that blocks the activation and amplification of the complement cascade by targeting C3.","indications":["Geographic atrophy (age-related macular degeneration)","C3 glomerulopathy","Post-transplant thrombotic microangiopathy"],"catalyst":""},{"name":"APL-9","genericName":"APL-9","slug":"apl-9","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"APL2","genericName":"APL2","slug":"apl2","phase":"phase_2","mechanism":"APL2 is a complement C3 inhibitor that blocks the central component of the complement cascade to reduce inflammation and tissue damage.","indications":["Paroxysmal nocturnal hemoglobinuria (PNH)","C3 glomerulopathy","Post-transplant thrombotic microangiopathy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQVll0dml1NGViZVZKR2k1MTRaSjdmTi1tMi13REN6SlQzWE5fZ2VMMk85ODRkQlFXVl9LYy1TRFgzVzRXcTd2UWRNUVBILS1TRHo1cDRhSGJTZkV0RkFITjdTcVBzNVRWRXUxWnJmLUdubm9vVUlLTlJZSDEtLXk5RFl0YXhwYms?oc=5","date":"2026-04-02","type":"deal","source":"MedCity News","summary":"Why Biogen Is Paying $5.6B to Buy Apellis Pharma - MedCity News","headline":"Why Biogen Is Paying $5.6B to Buy Apellis Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOVEV0VlhLbzVMaGdWYjJJLVN4V0NIVnVidDk2NW9vRzVpTTNwVDBZTl9aQW9Xd0FKQ3JTeXBvcUZpSTFQNHEwN3NRX1FTeUdfdVNlYWpDZlREb1lOd0RVemRNUG5WRnlHN3R1czVXN2NteVFqeV9hYzZybXZZWVkwTDZSNlFrQmJtNFBOUjZqZU9jRXFRRmFhNE1oNkVfM1ZrWEFIZ2FQclpuYmRYV09jVDdGSDZKZ1BPYnhXZHNIZw?oc=5","date":"2026-03-31","type":"deal","source":"Biogen","summary":"Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology - Biogen","headline":"Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Ou","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE94NnRjQzAtcXdjQkpVa2FpYlRmR01DNkd0U2lNZmNpb1NnczlHOWNqMmNfeHpDTHpjbDBqV2JsbTVrNncyZktyMVpELXg5azF1UUdTaGZVV3hGNVlkSGlvTDZPbThScm1PMnJBdDR1YlJVYnhBeXYtdjlqN0x2Y0HSAYQBQVVfeXFMTXBPUVNaZC1mclJIUGtpMlcwOVBlX25UOXhWekR2ZE5qbFBFLXdhMVVwVUI2Rkxrb21LVURNS0VVdW55Y0I1cTdteExrZDZjalJzaHppdEdqQmtGTEFQZUNlU0xjME1raU83MzJPTnpBZ0t5aDBVRUxEaGF3eEJOYXdtQ0NW?oc=5","date":"2026-03-31","type":"deal","source":"CNBC","summary":"Biogen to buy Apellis Pharmaceuticals for $5.6 billion in rare disease push - CNBC","headline":"Biogen to buy Apellis Pharmaceuticals for $5.6 billion in rare disease push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNbDJ3LUVwWFVocHdXak83eTYtd0N3YjNYZE1kNmI1NjFkRDlubkhGQkhweW1tZ1o0aTVhTGZOU295LU5xblJnTHZWWnE1c1FNSnVlMTMyTGl2V3hBRDRjTkstTC03S2hsX2c5V3h5QVhnY012YnBuMV9jclFfUXZlVmRlQXczdkVqc3pMbDV3Qm9ZSlowTTNlU0dmei16QUhaYlpTVQ?oc=5","date":"2026-03-31","type":"deal","source":"BioSpace","summary":"Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy - BioSpace","headline":"Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1iU3Y5dThQdVZIN1pSM19yQjhIeDB1QUxuV0VqZkR5VzVXY002ZVJGZVQzbi1MUWotcXlHWDdEYldxVTVaTjg3WjVOdUJWdURRa2ctWEpLVldVR3JkaHFWbjQ3NjYzZDJHaVJUQWFZNkpxSjB5azJiYg?oc=5","date":"2026-03-31","type":"pipeline","source":"Barron's","summary":"Apellis Stock More Than Doubles on Biogen News. Here’s What to Know. - Barron's","headline":"Apellis Stock More Than Doubles on Biogen News. Here’s What to Know. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOa1pUNWRyWTFWMl9sRk9GTDhkNW5YWVZQRWQ2enRTbGpIb0JxZzlxUDBNdE9QTmtJMHpVeFBNZnN0SHNmQmNqdUxseFB4QkMzRTY2Q1pnMFIwV0hpdDFmTDFEUXlIalZhYTZfSmlqODU2b0I2UjNNcVRtdFN0ZDVpdGVTblZPUzdVdWhTOEJTR19XWmdlSFA1VzNiLUFTU3NtNTRfVEZXbWFFbmxwWFhwZjl4SGo?oc=5","date":"2026-03-31","type":"deal","source":"Bloomberg.com","summary":"Biogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise - Bloomberg.com","headline":"Biogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxON0NZNkV2SnFaVFlwb2d5cEE3STdvNjZINkZsb3kwLTMyM3FXUWVaNEpwOWo0bnJCYUZKd0pVNkUxZzBIVE1xbTdzMndpS0pfRWhRcThIc3pBYmlmU1dlWUNpd0JhdlVIZnlScDI2aWdLQklqcVZzdTJhbTduenRWY3U5T01mZzdjQVVULUxXa3Q3V3BWQnVHWVNPUHpBZHFfcG5iWEh0VzdVaC1hckczOEJaZnNDOElXcHYyNnduUmhoWE1yS21kNlg4b3V0Zw?oc=5","date":"2026-03-31","type":"pipeline","source":"proactiveinvestors.com","summary":"Market movers: Apellis Pharmaceutical, Unilever, McCormick, Biogen... - proactiveinvestors.com","headline":"Market movers: Apellis Pharmaceutical, Unilever, McCormick, Biogen...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOQ1J4c2ZjcGtWcHBpR0xLckljLWF3eFpDRVBQV3RDbUVIbjdCMXBZelQ3U2x3c0FPMmdrX1VueC1TUFNTbXZNbU4xdTBwaFptT3hGaHJoU1ktV1dWMWhmeC15T29UWXZPaEJFRGI0cTlic0tUbFZwYUZjM3Q5WkpNaEJiYTlTbHY3bEU1X2FTMEtELTNESFVXQlRrX0paWEJacU5RWUZ2ejBIVGo4M2FoVUxvTmNZRlhIRF9kTw?oc=5","date":"2026-02-03","type":"earnings","source":"TradingView","summary":"5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView","headline":"5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9iVUFUYkF6aGt3akxZT0hGaW1LLTVITDlQdFFCYUZkc2IwaDJKSHZpQ1d2VmtPWldraV9yWm9idUZab0xqcWZzdXllQ1BIaF9WUGVxcFJMNWhPakFld2QzRVg2dElTbkZjVjdzcEY3QmtFRG96SzhTT25aMkY?oc=5","date":"2025-12-17","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Layoff Tracker 2025: Voyager jettisons 30 staffers; Mythic and Areteia shutter - Fierce Biotech","headline":"Fierce Biotech Layoff Tracker 2025: Voyager jettisons 30 staffers; Mythic and Areteia shutter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOVXE3Q2RUSG5zdkpmbWZNSExOTGlrNWZ3SkVkVHZmc0R2Y21xNzVpMlJxMjZGSzQ1bk5iUGFPU1pLWXRabkhxVmoyZFBhZkFQNktZWVNsa0ROOG5lMGRzMUdCTUZSdjhXejNHcU5wb1dTRUw1X1FMWmtoek5OeDNyR3hvejBwampNNUNoZkp6dkUwaVU1enJHVFBXWElqSTFMLUpacUdsMkQ?oc=5","date":"2025-12-12","type":"pipeline","source":"Seeking Alpha","summary":"Apellis Pharmaceuticals: A Good Product That Just Misses The Mark (NASDAQ:APLS) - Seeking Alpha","headline":"Apellis Pharmaceuticals: A Good Product That Just Misses The Mark (NASDAQ:APLS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPbkE4dTBpM2Z2aXJJemgzV3BrRmV5ZXlRelpwamlRckpmaUZqc2JlTVNOUzU1bXRFSDN3MGtGUmFhZElicExTWGJQQWg4LW5uUWdiZnN3clhONWdOejE2VHA5QlNqOVVqUm1ucmx6djY2R1haWGpGOTlvV2hVOTRzbHNRS0hjRDROSkhGSmZ0akMwZExEZWwza0tvbV91SG94d1hZYUgtMWlMdUw4X1otcmtjVHgyN25pbXM2TXN0NHJaYzNnUEtENmhScDVnLVhTVjRoLVhoTmdOMFQtYlhKQkk5OHFjdTA?oc=5","date":"2025-11-12","type":"pipeline","source":"Benzinga","summary":"What's Going On With Apellis Pharma Stock Wednesday? - Apellis Pharmaceuticals (NASDAQ:APLS) - Benzinga","headline":"What's Going On With Apellis Pharma Stock Wednesday? - Apellis Pharmaceuticals (NASDAQ:APLS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQX3NMT05KQmFKTFp5VWVvMzZIdUpLUmRFdEdUM1lhWlZfZG5TaFRnWVpaSFU0LVdST25uU0FjdlZvSy1NX1hFWERZWE1qZWstcGNDSTlaMnV3RktRa0tUdWZYMzJVa1Y1TzlFQktoSllibTZqMFJ6QUJVdHF6ZVdXZUVNbW9VcV8zWXR6SFk0TnZRQU5FRUIzTWo1M2U0Y1QwbUM3NVdtWUd6VElxb0lBYUVQUEtpQQ?oc=5","date":"2025-05-14","type":"earnings","source":"Fierce Pharma","summary":"Apellis' weak quarter for Syfovre signals uphill climb for geographic atrophy med: analyst - Fierce Pharma","headline":"Apellis' weak quarter for Syfovre signals uphill climb for geographic atrophy med: analyst","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":2,"marketed":1,"phase_1":1,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}